Compare RLX Technology Inc (RLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs State Street SPDR S&P Biotech ETF — how do they compare? RLX Technology Inc trades at $2.02 (market cap $2.42B), while State Street SPDR S&P Biotech ETF trades at $159.21. The key difference: RLX Technology Inc pays a 5.05% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, RLX Technology Inc nearer its low. Which is the better fit depends on your goals.
| RLX | XBI | |
|---|---|---|
Market Cap | $2.42B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.73 | $164.28 |
52-Week Low | $1.79 | $86.92 |
Enterprise Value | $1.04B | — |
Dividend Yield | 5.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $2.02, up 1.0% today, amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 22.47% net margins and solid cash flow generation, though recent quarterly earnings have missed expectations. International expansion remains a key growth driver, with overseas revenue now exceeding 70% of total sales following the Totally Wicked acquisition.
While RLX maintains strong fundamentals and cash reserves, the bearish technical outlook and recent earnings misses create near-term uncertainty. The company's international growth strategy offers potential upside, but regulatory risks in the vaping industry and execution challenges pose significant headwinds for investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
